Venetoclax monotherapy as front-line therapy for blastic plasmacytoid dendritic cell neoplasm
Venetoclax is an approved treatment for relapsed/refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). We report a unique case of venetoclax monotherapy used for front-line induction and as a bridge to allogeneic hematopoietic stem cell transplantation (HCT). Venetoclax therapy resulted i...
Main Authors: | Ankit Mitesh Shah, Denise Pereira, Julio Poveda, Trent Peng Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-01-01
|
Series: | Leukemia Research Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213048923000201 |
Similar Items
-
Therapeutic Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Allogeneic Hematopoietic Cell Transplantation and Novel Therapies
by: Mohamed A. Kharfan-Dabaja, et al.
Published: (2019-03-01) -
Pseudo-Rosette-Forming Blastic Plasmacytoid Dendritic Cell Neoplasm
by: Praveen Sharma, et al.
Published: (2020-08-01) -
Rapid Progression of Blastic Plasmacytoid Dendritic Cell Neoplasm without Extracutaneous Manifestation
by: Guohua Yu, et al.
Published: (2015-02-01) -
Blastic plasmacytoid dendritic cell neoplasm: a short review and update
by: Cesare Massone, et al.
Published: (2023-08-01) -
A Case of Blastic Plasmacytoid Dendritic Cell Neoplasm with Unusual Presentation
by: Sneha Dhariwal, et al.
Published: (2019-02-01)